NasdaqGS:APLSBiotechs
Assessing Apellis Pharmaceuticals (APLS) Valuation After Mixed Returns And High P/E Versus DCF Fair Value Estimate
Recent share performance and business snapshot
Apellis Pharmaceuticals (APLS) has drawn investor attention after recent share price moves, with the stock showing mixed returns over the past year and a market reaction that contrasts with its more recent monthly performance.
The share price is up about 11% over the past month and around 14% over the past 3 months, while the 1 year total return is a decline of roughly 22%, and the 3 year total return is a decline of about 66%.
Year to date, the...